NEW JERSEY--(BUSINESS WIRE)--JP Errico CEO of electroceutical healthcare company electroCore has spearheaded an overhaul of the companys’ management structure over the last two years. Its top team now better reflects its extensive global ambitions and its culture of professionalism and continuous improvement.
JP commented, “We are moving into a period of rapid growth as we start to bring our therapies to market across the globe. To meet this challenge we have strengthened our management team with a new focus on the commercialization of our non-invasive vagus nerve stimulation nVNS therapy for headache – cluster and migraine - and to further expand the use of nVNS therapies in gastric motility disorders, bronchoconstriction, epilepsy, depression and anxiety. Initially our commercial efforts are focused on headache in Europe, Australia and Canada where we have regulatory approval. In the US we are presently completing the necessary FDA pivotal trial for submission in 2014.”
The electroCore Global Executive Team comprises;
JP Errico, Chief Executive, who founded the company in 2005, has started a number of very successful medical device companies, including Fastenetix, K2 Medical, AD-4 Pharma, E2, and SpineCore. Products conceived by these companies have generated more than $8 billion in sales to date.
Frank Amato, Chief Operating Officer who has extensive commercial pharma experience including Vice President of the Specialty Commercial Operations Group, Merck and Executive Director, Global Business Operations, Schering-Plough joined electroCore in 2011.
Bruce J. Simon, PhD Vice President of Research who spent 16 years as Senior Director of Research at EBI (a division of Biomet, Inc.) where he directed research on the effects of electric and electromagnetic fields on bone, cartilage and soft tissue repair. Bruce joined in 2008.
Steve Mendez, Founder, Chief Science Officer is a research and development executive with 28 years experience driving all phases of product life cycle from concept/patents and design to manufacturing and sales/field support. Steve was previously Vice President of Development with the EBI division of Biomet.
Mike Romaniw, Vice President, Quality Assurance is a quality assurance and regulatory compliance expert with 35 years experience in the medical device industry, including manufacturing, design and development, and quality management. Mike was previously Director of Quality Assurance and Regulatory Compliance at Blackstone Medical, Inc. and joined electroCore in 2011.
Jason Pesile, Vice President, Finance spent nine years in management consulting, advising a range of life sciences companies on financial, operational and HR matters. He spent 5 years in the pharmaceutical industry – at Merck and Schering-Plough – where he worked on a variety of corporate strategic initiatives. Jason joined electroCore in 2011.
Eric Liebler Vice President, Scientific, Medical and Governmental Affairs has more than 20 years of neurological industry and association experience including co-founding Nautilus Neurosciences, which brought Cambia® for the treatment of acute migraine to market Erichas held leadership positions at Elan, Amarin, Enzon Pharmaceuticals, Questcor Pharmaceuticals, and Pharmacopeia and joined electroCore in 2012.
The most recent addition is Bob Griffing Vice President Global Sales and Marketing who joined in September this year. Prior to joining electroCore Bob spent over 22 years at Merck where he rose to be Vice President of Primary Care Commercial Operations for the Southeast, Global Brand Leader, Oncology Products and National Sales Director, Neuropsychiatry.
A new regional commercial structure being built in Germany - reporting to COO Frank Amato - will support Europe, Australia and Canada.
The management team is supported by a strong board of directors composed of senior executives drawn from business, pharma, medical devices and medicine.
Full resume of management and board is available at; www.electrocoremedical.com/officers-directors